​

Centessa Pharmaceuticals (CNTA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CNTA Stock Forecast

Centessa Pharmaceuticals (CNTA) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $27.50, with a high of $28.00 and a low of $27.00. This represents a 100.44% increase from the last price of $13.72.

$5 $10 $15 $20 $25 $30 High: $28 Avg: $27.5 Low: $27 Last Closed Price: $13.72

CNTA Stock Rating

Centessa Pharmaceuticals stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

CNTA Price Target Upside V Benchmarks

TypeNameUpside
StockCentessa Pharmaceuticals100.44%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$27.00$22.50
Last Closing Price$13.72$13.72$13.72
Upside/Downside-96.79%63.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2537---10
Mar, 2527---9
Feb, 2527---9
Jan, 2527---9
Dec, 2426---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 07, 2025Morgan Stanley$27.00$16.2366.36%96.79%
Nov 15, 2024Debjit ChattopadhyayGuggenheim$28.00$17.1063.74%104.08%
Sep 19, 2024Jeffrey HungMorgan Stanley$26.00$15.8564.04%89.50%
Sep 11, 2024Kelly ShiJefferies$19.00$14.9926.75%38.48%
Sep 10, 2024Kostas BiliourisBMO Capital$20.00$16.0224.84%45.77%
Aug 14, 2024Kostas BiliourisBMO Capital$15.00$12.6019.05%9.33%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024GuggenheimBuyBuyhold
Sep 19, 2024Morgan StanleyEqual-WeightOverweightupgrade
Sep 18, 2024B. RileyBuyinitialise
Sep 11, 2024JefferiesBuyBuyhold
Sep 11, 2024GuggenheimBuyBuyhold
Sep 09, 2024BMO CapitalOutperformOutperformhold
Aug 14, 2024BMO CapitalOutperformOutperformhold
Jul 18, 2024OppenheimerOutperforminitialise
Jun 21, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Aug 12, 2022Morgan StanleyOverweightUnderweightdowngrade

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.57$-2.06----
Avg Forecast$-1.63$-1.52$-1.55$-1.73$-2.03$-1.24
High Forecast$-1.57$-1.43$-1.12$-1.07$-1.11$-1.24
Low Forecast$-1.69$-1.78$-1.81$-2.00$-2.62$-1.24
Surprise %-3.68%35.53%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.85M-----
Avg Forecast$6.85M$6.85M$269.50K$3.78M$40.90M$148.00M
High Forecast$6.85M$6.85M$269.75K$3.78M$40.90M$148.00M
Low Forecast$6.85M$6.85M$269.25K$3.78M$40.90M$148.00M
Surprise %------

Net Income Forecast

$-300M $-260M $-220M $-180M $-140M $-100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-151.09M$-235.76M----
Avg Forecast$-151.09M$-161.26M$-141.22M$-147.35M$-251.32M$-118.94M
High Forecast$-150.62M$-137.35M$-108.02M$-102.63M$-106.36M$-118.94M
Low Forecast$-162.13M$-171.23M$-174.41M$-192.06M$-251.91M$-118.94M
Surprise %-46.19%----

CNTA Forecast FAQ

Is Centessa Pharmaceuticals stock a buy?

Centessa Pharmaceuticals stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Centessa Pharmaceuticals is a favorable investment for most analysts.

What is Centessa Pharmaceuticals's price target?

Centessa Pharmaceuticals's price target, set by 7 Wall Street analysts, averages $27.5 over the next 12 months. The price target range spans from $27 at the low end to $28 at the high end, suggesting a potential 100.44% change from the previous closing price of $13.72.

How does Centessa Pharmaceuticals stock forecast compare to its benchmarks?

Centessa Pharmaceuticals's stock forecast shows a 100.44% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and outperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Centessa Pharmaceuticals over the past three months?

  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 77.78% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Centessa Pharmaceuticals’s EPS forecast?

Centessa Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.55, marking a -24.76% decrease from the reported $-2.06 in 2024. Estimates for the following years are $-1.73 in 2026, $-2.03 in 2027, and $-1.24 in 2028.

What is Centessa Pharmaceuticals’s revenue forecast?

Centessa Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $269.5K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $3.78M, followed by $40.9M for 2027, and $148M for 2028.

What is Centessa Pharmaceuticals’s net income forecast?

Centessa Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-141M, representing a -40.10% decrease from the reported $-236M in 2024. Projections indicate $-147M in 2026, $-251M in 2027, and $-119M in 2028.